ABSTRACT
Dr. Borer (Moderator): Dr. Singh, it seems from your comments that it may not be necessary to measure silent ischemia in an antianginal drug development program in the U.K. This would be consistent with U.S. policy. Will you clarify the U.K. position on this point?
